Anixa Biosciences Files DEF 14A Detailing Executive Compensation

TL;DR

Anixa Biosciences DEF 14A out: exec comp & stock options for FY24 detailed.

AI Summary

Anixa Biosciences Inc. filed its DEF 14A on February 6, 2025, for the fiscal year ending October 31, 2024. The filing details executive compensation and stock option awards granted during the fiscal years 2021-2024. It includes the fair value of option awards granted to both PEO (Principal Executive Officer) and Non-PEO Neo Members.

Why It Matters

This filing provides transparency into how Anixa Biosciences compensates its top executives and the potential value of stock options granted, which can impact shareholder value and executive incentives.

Risk Assessment

Risk Level: medium — DEF 14A filings are routine disclosures, but the details on executive compensation and stock awards can reveal potential dilution or significant incentive structures that may affect stock price.

Key Numbers

• 2024 — Fiscal Year End (The filing covers the fiscal year ending October 31, 2024.)
• 2021-2024 — Option Award Grant Periods (Details on stock option awards are provided for fiscal years 2021 through 2024.)

Key Players & Entities

• Anixa Biosciences Inc. (company) — Filer of the DEF 14A
• 0001493152-25-005199 (document_id) — Accession Number for the filing
• 20250206 (date) — Filing Date
• 20241031 (date) — Fiscal Year End

FAQ

Key Financial Figures

• $0.01 — d shares of our common stock, par value $0.01 per share (" Common Stock "), on Januar

Filing Documents

• formdef14a.htm (DEF 14A) — 466KB
• def14a_001.jpg (GRAPHIC) — 26KB
• def14a_002.jpg (GRAPHIC) — 25KB
• 0001493152-25-005199.txt ( ) — 1109KB
• anix-20241031.xsd (EX-101.SCH) — 5KB
• anix-20241031_def.xml (EX-101.DEF) — 8KB
• anix-20241031_lab.xml (EX-101.LAB) — 61KB
• anix-20241031_pre.xml (EX-101.PRE) — 43KB
• formdef14a_htm.xml (XML) — 97KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 Anixa Biosciences, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. 1) Title of each class of securities to which transaction applies: 2) Aggregate number of securities to which transaction applies: 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11: 4) Proposed maximum aggregate value of transaction: 5) Total fee paid: Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: ANIXA BIOSCIENCES, INC. 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 February 6, 2025 To the Stockholders of Anixa Biosciences, Inc.: You are cordially invited to attend the 2025 Annual Meeting of Stockholders (the " Virtual Meeting ") of Anixa Biosciences, Inc. (the " Company ") to be held on a virtual basis on Thursday, March 20, 2025 at 10:00 a.m. Pacific Time, for the following purposes: 1. To elect Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. as directors (the " Director Nominees ") to serve on the Company's Board of Directors (the " Board ") for a one-year term that expires at the 2026 Annual Meeting of Stockholders, or until their successors are elected and qualified; 2. To approve on a non-binding, advisory basis the compensation of our named executive officers; 3. To ratify the appointment by the Board of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending October 31, 2025; 4. To select on a non-binding, advisory basis the frequency of conducting future stockholder advisory votes on named executive officer compensation (which will be either every year, every two years or every three years); and 5. To transact such other business as may properly come before the Virtual Meeting or any adjournment thereof. THE BOARD UNANIMOUSLY RECOMMENDS A VOTE FOR THE ELECTION OF EACH OF THE DIRECTOR NOMINEES, A vote FOR the approval on a non-binding, advisory basis, of the compensation of our named executive officers, A VOTE FOR THE RATIFICATION OF THE APPOINTMENT OF THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING OCTOBER 31, 2025 and A VOTE FOR ONE YEAR FOR THE FREQUENCY OF CONDUCTING FUTURE STOCKHOLDER ADVISORY VOTES ON NAMED EXECUTIVE OFFICER COMPENSATION. The Board has fixed the close of business on January 23, 2025 as the record date (the " Record Date ") for the determination of stockholders entitled to notice of, and to vote at, the Virtual Meeting or any postponement or adjournment thereof. Accordingly, only stockholders of record at the close of business on the Record Date are entitled to notice of, and shall be entitled to vote at, the Virtual Meeting or any postponement or adjournment thereof. Your vote is important. You are requested to carefully read the Proxy Statement and accompanying Notice of Annual Meeting for a more complete Sincerely yours, /s/ Dr. Amit Kumar Dr. Amit Kumar Chairman and Chief Executive Officer Anixa Biosciences, Inc. IMPORTANT WHETHER OR NOT YOU EXPECT TO ATTEND THE VIRTUAL MEETING, please read the proxy statement and promptly vote your proxy VIA the internet, by telephone or, if you received a printed form of proxy in the mail, by completing, dating, signing and returning the enclosed proxy IN ORDER TO ASSURE REPRESENTATION OF YOUR SHARES AT THE VIRTUAL MEETING. YOUR PROXY, GIVEN THROUGH THE RETURN OF THE PROXY CARD, MAY BE REVOKED PRIOR TO ITS EXERCISE BY FILING WITH OUR CORPORATE SECRETARY PRIOR TO THE VIRTUAL MEETING A WRITTEN NOTICE OF REVOCATION OR A DULY EXECUTED PROXY BEARING A LATER DATE, OR BY ATTENDING THE VIRTUAL MEETING AND VOTING. IF YOU HAVE ALREADY VOTED OR DELIVERED YOUR PROXY FOR THE VIRTUAL MEETING, YOUR VOTE WILL BE COUNTED, AND YOU DO NOT HAVE TO VOTE YOUR SHARES AGAIN. IF Y

View Full Filing

View this DEF 14A filing on SEC EDGAR